TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05804097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
Study: NCT05870774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation with CTG
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Harvesting of free connective tissue graft from the maxilla tuberosity area~4. Fixation of the graft to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation with CM
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly
Study: NCT05441761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
Description: Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study: NCT05158699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
Description: Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
Description: Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
Study: NCT06174272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Care Program
Description: Intensive monitoring post discharge for cirrhosis and fluid overload
Study: NCT05299671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video consultation
Description: During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
Study: NCT06586320

Intervention type: DEVICE
Group type: OTHER
Intervention: Evaluation of mathematical models
Description: Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras
Study: NCT05634031

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: PET imaging visit, which will take approximately 1-2 hours.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Coronary CT angiogram
Description: A coronary CT angiogram if the participant has not had one recently.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Angiography
Description: A subset of patients with abnormal results on cardiac PET myocardial perfusion imaging study (estimated number of patients = 12) will be invited to participate in an invasive sub-study wherein they would undergo detailed invasive coronary physiology evaluation.~Functional Angiography (coronary reactivity test- CRT): is an angiography procedure done in the catheterization laboratory. It evaluates the coronary artery microcirculation and how the blood vessels respond to different medications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treadmill exercise stress study
Description: A treadmill exercise stress study
Study: NCT06146205

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct lateral approach
Description: The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPAIRE
Description: The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
Study: NCT06393868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg Oral Tablet
Description: Omeprazole once daily for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 90 days
Study: NCT05737849

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.
Study: NCT06223919

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LC16m8
Description: LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC16m8
Description: LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses
Study: NCT06450080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI and MRS acquisitions
Description: All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and MRS acquisitions
Description: All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .
Study: NCT05731323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulator
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
Study: NCT05008562

Intervention type: OTHER
Intervention: COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT
Description: there is no interventions to the patients.
Study: NCT06613841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.
Study: NCT06523166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Description: TEE will be performed using a 3D probe. TEE images will be acquired at the standard 0, 45, 90, and 135 degree views along with a 3D acquisition encompassing the entire LAA, device, left pulmonary vein and lateral mitral annular landmarks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac CTA
Description: Cardiac CTA will be performed with ECG gating using systems with ≥ 64 detector rows and with temporal resolution that is at least 175 msec (rotation speed ≤ 350 msec for single source systems). Cardiac CTA images will be acquired for the entire cardiac cycle without ECG phase specific pulsing and with contrast appropriately timed for peak left atrial/arterial phase contrast enhancement. In addition, a targeted end systolic only delayed phase image set (45 seconds after the arterial phase scan and limited to the left atrium and appendage device) will be acquired.
Study: NCT06621472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrolaminar block technique
Description: patients will be placed in a sitting position. The transducer will be positioned vertically 3 cm lateral to the midline at the level of the 7th thoracic transverse process. The muscles of the back, the transverse process, and the pleura between two transverse processes will be visualized. The needle will be introduced in a cranial-caudal direction toward the lamina using the in-plane method until the tip lay in the lamina 1 mL of normal saline will be injected to confirm the correct needle tip position by visualizing the spread. After negative aspiration, 20 mL of 0.25% isobaric bupivacaine. The procedure will be repeated on the opposite side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subcostal TAP technique
Description: The transducer will be placed obliquely along the subcostal margin near the xiphisternum in the midline of the abdomen. The rectus abdominis muscle and underlying transversus abdominis muscle will be identified. The position of the transversus abdominis muscle will be confirmed by sliding the transducer laterally until the aponeuroses of the external and internal oblique muscle will be visualized. The transversus abdominis muscle will be then identified, being posterior to the internal oblique muscle and will be followed back medially to confirm its position beneath the rectus muscle. the needle will be introduced through the rectus muscle in a superomedial-to-inferolateral direction towards the transversus abdominis muscle using the in-plane method, and 20 mL of 0.25% isobaric bupivacaine will be injected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic Epidural
Description: Before induction of general anesthesia the epidural catheter was inserted under sterile condition with a loss of resistance technique by an 18G needle at a mid-thoracic level (Th 7-10) to cover the dermatomes innervating the incision in the upper abdomen. The epidural infusion consisting of bupivacaine 1 mg/mL, and fentanyl 2 μg/mL was activated on the attending anesthesiologist's decision. Following the hospital protocols, the infusion rate was initiated at 5-10 mL/h, increased to maximum 15 mL/h if necessary, bolus dose of 5 mL was allowed every 30 minutes.
Study: NCT04516434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure-flow study
Description: A pressure flow study will be performed to evaluate voiding function after stimulation. The transurethral and intra-vaginal catheters are left in place after cystometry and the participant will be asked to void around them, into a commode. Bladder and abdominal pressures will be recorded, as well as urine flow over time.
Study: NCT04946370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitor
Description: Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitor
Description: Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: \[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: \[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
Study: NCT05629923

Intervention type: DRUG
Intervention: tixagevimab-cilgavimab(AZD7442, AstraZeneca)
Description: In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
Study: NCT04798638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 Tablets under Fasted Condition - Arm1
Description: Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Study: NCT04635280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking
Description: A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and an algorithm.
Study: NCT06638372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffeine
Description: The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
Study: NCT06636799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling only
Description: In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left.
Study: NCT04798638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate Tablets under Fasted Condition - Arm1
Description: Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 Tablets after a High-fat Meal - Arm1
Description: Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate Tablets under Fasted Condition - Arm2
Description: Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 Tablets under Fasted Condition - Arm2
Description: Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 Tablets after a High-fat Meal - Arm2
Description: Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Study: NCT06636799

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling and actives
Description: In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left. Group G3 received microneedling associated with active ingredients. This manipulated active ingredient was composed of growth factors (EGF Factor, TGFß3 Factor, and IDP-2 Peptide), Hydroxyprolisilane, and hyaluronic acid.
Study: NCT06638437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: The mobile application will include the following modules:~1. Psychoeducation: information about what to expect from each phase of the surgical process (i.e., pre-operative, the surgery itself and the post-operative).~2. Activation control techniques: to teach different activation control techniques such as relaxation, breathing techniques and mindfulness training.~3. Cognitive restructuring and problem solving: to teach how to change maladaptive pain-related beliefs for more adaptive ones and how to better cope with pain.~4. Exercises and tasks: to encourage the use of the learning strategies we will offer a number of exercises and tasks~5. Parent's module: to teach parents about the surgical process and how they can help their children during the process
Study: NCT06637397

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
Study: NCT06637761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoMTA2
Description: Bio-active bio-ceramic mineral trioxide aggregate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WMTA
Description: White Mineral trioxide aggregates
Study: NCT06640283

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ctDNA test
Description: ctDNA involves the collection of peripheral blood samples for the analysis of circulating tumor DNA (ctDNA). The samples are processed using next-generation sequencing (NGS) and/or digital polymerase chain reaction (PCR) techniques to detect specific genetic alterations related to the tumor. The objective is to assess the presence and quantity of ctDNA, providing information on tumor burden and treatment response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive the institution's standard treatment during Phase I. If ctDNA remains positive between 8 and 12 weeks after the standard treatment, the participant will be invited to proceed to Phase II, which will consist of intravenous immunotherapy for up to 12 months, or until disease progression or unacceptable toxicity occurs. Continuous monitoring with ctDNA testing will be performed during Phase II.
Study: NCT06638944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person sEMG-biofeedback
Description: Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions in the clinic and 3 days of home practice per week using the i-Phagia sEMG system. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients use the sensor patch and the software guides them on how to complete the exercises and receive feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote sEMG-biofeedback
Description: Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions completed remotely (via telehealth) and 3 days of home practice per week. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients also use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
Study: NCT05402917

Intervention type: PROCEDURE
Intervention: Erector Spinae Plane Block
Description: Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.